For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Blueprint Medicines Corp’s stock clocked out at $128.10, up 0.39% from its previous closing price of $127.60. In other words, the price has increased by $0.39 from its previous closing price. On the day, 8.9 million shares were traded.
Ratios:
To gain a deeper understanding of BPMC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 2.08 whereas as Long-Term Debt/Eq ratio is at 1.72.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 27 ’25 when Albers Jeffrey W. sold 5,000 shares for $101.14 per share. The transaction valued at 505,692 led to the insider holds 146,630 shares of the business.
Albers Jeffrey W. bought 5,000 shares of BPMC for $505,686 on May 27 ’25. On May 19 ’25, another insider, Rossi Christina, who serves as the CHIEF OPERATING OFFICER of the company, sold 2,274 shares for $100.51 each. As a result, the insider received 228,557 and left with 64,718 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 14.72 while its Price-to-Book (P/B) ratio in mrq is 24.17.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $128.15, while it has fallen to a 52-week low of $73.04. The 50-Day Moving Average of the stock is 35.92%, while the 200-Day Moving Average is calculated to be 36.32%.
Shares Statistics:
A total of 64.56M shares are outstanding, with a floating share count of 62.21M. Insiders hold about 3.67% of the company’s shares, while institutions hold 106.96% stake in the company.
